In the last 2 years $6,228,912 has been spent by the Wangle Directors and management on Research, development, consultants, directors fees, salaries, superannuation, legal fees, corporate fees, advertising and marketing, administration and corporate costs.
This spend has given shareholders a share price of .003 with massive dilution, continual suspensions from trading and debt.
Revenue for 2017/2018 - $12,000.
.........what next.
Currently we have one product that is not bringing in revenue and the other one that the company was originally built on, has disappeared off the radar.
Maybe an announcement that outlines in detail the plans moving forward with specific timing, associated costs and expected revenue.
Or the alternative, more of the same unknown path ahead, unknown issues still to be dealt yet to arise and then the eventual demise into obscurity.
Why not put the "details" on the table, the shareholder value is on its knees with another set of vultures waiting to pick the carcass of whats left of the remaining CR funds.
- Forums
- ASX - By Stock
- FGL
- Skoolbag agreement
Skoolbag agreement, page-16
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FGL (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.631M |
Open | High | Low | Value | Volume |
1.5¢ | 1.6¢ | 1.4¢ | $25.52K | 1.757M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13717 | 1.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.5¢ | 5286 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13717 | 0.014 |
2 | 110000 | 0.013 |
5 | 939666 | 0.012 |
1 | 90000 | 0.011 |
1 | 50000 | 0.010 |
Price($) | Vol. | No. |
---|---|---|
0.015 | 5286 | 1 |
0.016 | 187896 | 2 |
0.017 | 77000 | 1 |
0.018 | 81000 | 1 |
0.019 | 91000 | 1 |
Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
Featured News
FGL (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, MD & CEO
Charles Armstrong
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online